Dataset Information


The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.

ABSTRACT: A common deletion polymorphism within B-cell chronic lymphocytic leukemia-lymphoma like 11 gene (BIM) was deemed to be a genetic cause leading to compromised kinase inhibitor therapeutic efficacy in cancer individuals. However, the results reported were not consistent. Thus, a comprehensive meta-analysis containing 12 eligible studies including 1,532 Asian patients was conducted to investigate a steady and reliable conclusion. The results showed that BIM deletion polymorphism was significantly associated with tyrosine kinase inhibitor (TKI) clinical efficacy in term of response rate (Ph = 0.349, HR = 0.438, 95%CI = 0.274-0.699) and disease control rate (Ph = 0.941, HR = 0.370, 95%CI = 0.202-0.678) in EGFR-mutated NSCLC population, not in CML and HCC subgroups. Additionally, EGFR-mutated NSCLC patient harbored BIM deletion polymorphism was associated with a shorter progression-free survival (PFS) than those with BIM wild polymorphism (Ph = 0.580, adjusted HR = 2.194, 95%CI = 1.710-2.814). However, no significant association was examined between BIM deletion polymorphism and overall survival (OS) and toxic adverse events in EGFR-mutated NSCLC population and it was not associated with PFS and OS in HCC subgroup. These findings revealed that BIM deletion polymorphism might be a genetic cause of intrinsic resistance to TKI therapy and it could be emerged as an independent predictor to identify patients who would benefit from TKI targeted therapy in EGFR-mutated NSCLC.


PROVIDER: S-EPMC4466895 | BioStudies | 2015-01-01

SECONDARY ACCESSION(S): 10.1038/srep11348

REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC7004511 | BioStudies
2017-01-01 | S-EPMC5522319 | BioStudies
1000-01-01 | S-EPMC5388210 | BioStudies
2019-01-01 | S-EPMC6397445 | BioStudies
1000-01-01 | S-EPMC3635875 | BioStudies
1000-01-01 | S-EPMC5356566 | BioStudies
2020-01-01 | S-EPMC7240862 | BioStudies
2019-01-01 | S-EPMC6815404 | BioStudies
2018-01-01 | S-EPMC6299879 | BioStudies
2018-01-01 | S-EPMC6132175 | BioStudies